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Abstract: Men are more likely to develop cancer than women. In fact, male predominance is one
of the most consistent cancer epidemiology findings. Additionally, men have a poorer prognosis
and an increased risk of secondary malignancies compared to women. These differences have been
investigated in order to better understand cancer and to better treat both men and women. In this
review, we discuss factors that may cause this gender difference, focusing on urothelial bladder
cancer (UBC) pathogenesis. We consider physiological factors that may cause higher male cancer
rates, including differences in X chromosome gene expression. We discuss how androgens may
promote bladder cancer development directly by stimulating bladder urothelium and indirectly
by suppressing immunity. We are particularly interested in the role of natural killer (NK) cells in
anti-cancer immunity.
Keywords: urothelial bladder cancer; natural killer cells; androgens; immunosuppression; X chromo-
some; sex factors
1. Introduction
The Gender Divide: “Instead of Ignoring Our Differences, We Need to Accept and
Transcend Them.” Sheryl Sandberg [1].
UBC is common, with a 2.4% lifetime risk [2]. UBC is much more common in men:
out of the estimated 83,750 new UBC cases in America in 2021, about 64,280 are in men and
19,450 are in women [3]. UBC also kills more men than women: in 2021 it is estimated to
kill 12,260 men and 4940 women [3]. Even when controlling for increased male exposure
to carcinogens, such as tobacco and industrial chemicals, men are at an increased risk [4].
Gender differences in cancer outcomes can be due to biological or social factors. For
example, well-known variances in occupation, workplace exposures, and social networks
could all influence cancer incidence and survival, but not be directly due to biological
sex. Furthermore, physicians sometimes treat male and female patients differently. In this
review, we focus on biological sex differences that may affect UBC incidence and mortality.
As we discuss below, observed UBC gender differences could be related to how androgens
and the androgen receptor (AR) affect UBC development and progression. UBC gender
disparity also could result if androgens suppress anti-cancer immunity. Moreover, greater
transcription of some X chromosome genes may protect females from UBC.
Most UBC cases are identified early and are transurethrally resected. Adjuvant
treatment often includes intravesicular infusion of cytotoxic chemotherapy or of bacil-
lus Calmette-Guerin (BCG) immunotherapy. While non-muscle-invasive bladder cancer
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(NMIBC) tumors often respond to these treatments, UBC has a lifetime recurrence risk
of up to 50% and requires long-term monitoring [5,6]. As a result, UBC treatment and
monitoring cost more than for any other cancer [7,8]. It should be emphasized that UBC
5-year mortality rates have remained fairly consistent over the last three decades, despite
advancements in treatment [2]. To help current and future patients, we must further study
UBC pathogenesis. This review focuses on proposed biological reasons for high male
incidence, which leads to more male deaths. What we learn from gender differences may
allow us to better understand and treat UBC in both sexes.
2. The Androgen Receptor in Bladder Cancer
Encoded on the X chromosome, the androgen receptor (AR) binds to testosterone and
related hormones. Testosterone stimulates cells through multiple mechanisms (Figure 1).
In the classical mechanism [9], the hormone passively diffuses into the cell and binds
cytoplasmic AR. Increasing potency, testosterone is reduced by 5-α reductases in the
cytoplasm to dihydrotestosterone (DHT), which binds to AR with high affinity. Hormone
binding changes AR conformation, which allows hormone–AR complexes to enter the
nucleus and either enhance or depress transcription of multiple genes [9]. In addition, AR
interacts with important cytoplasmic signaling molecules, including PI3K, Src, and Ras, to
initiate MAP kinase signaling [10]. In another non-classical mechanism, ZIP9 (SLC29A9)
was identified as a non-AR cell surface androgen receptor (Figure 1). Upon testosterone
binding, ZIP9 increased intracellular zinc and imparted an apoptotic signal [11,12]. A
putative T-lymphocyte surface androgen receptor [13–15] may, in retrospect, have been
ZIP9. Finally, IL-6 and IL-8 inflammatory cytokines activate AR signaling in the absence of
androgens (Figure 1), via ERK, Src, FAK, and STAT3 [16,17]. AR is widely expressed in both
sexes, despite large differences in androgen levels. Both sexes express AR in the bladder,
including urothelium, muscularis propria (detrusor muscle), and bladder neurons [18–20].
In castrated male rats, androgen replacement therapy significantly improved urothelial
thickness and muscle fiber quantity, indicating an androgen effect on these structures [21].
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Figure 1. Schematic representation of androgen and AR signaling mechanisms in cells. 
Figure 1. Schematic representation of androgen and AR signaling mechanisms in cells.
High overall male cancer risk naturally suggests that AR and testosterone accelerate
cancer initiation, progression, or metastasis. For prostate cancer (PCa), this relationship is
well established [22–24]. In addition to PCa, many cancers are influenced by androgens.
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For example, castration of male rats reduced both chemically induced pancreatic tumor
burden and renal cell carcinoma; testosterone administration at least partly reversed this
effect [25]. However, particularly aggressive cancers often do not respond to androgen
deprivation therapy (ADT). Castration-resistant PCa is a classic example. It most often
arises after ADT, which selects for highly aggressive castration-resistant cancer cells that
proliferate, have stem cell-like properties, and survive chemotherapy [26]. Recent work
has suggested a mechanism by which this may occur—Schroeder et al. [27] found that in
mice, the AR antagonist, flutamide, caused PCa cells to convert to a cancer stem cell (CSC)
phenotype. The process was mediated through STAT3 signaling induced by IL-6 [27,28]. As
noted above, STAT3 stimulates AR in an androgen-independent mechanism [17]. Blocking
mouse IL-6 mice significantly reduced PCa stem cell numbers [27].
As a general principle, hormone-resistant cancers may arise from hormone-sensitive
tissue. Breast cancers often are treated with tamoxifen, a selective estrogen receptor
modulator that inhibits estrogen actions in breast tissue. However, some breast cancers
resist hormone-based therapy. Many molecular mechanisms allow breast cancers to lose
estrogen sensitivity [29]. Breast cancers that lose estrogen sensitivity typically have a
more aggressive course and poorly respond to chemotherapy [30]. A notable example
is triple-negative breast cancer (negative for ERBB2 (Her2/neu), estrogen receptor, and
progesterone receptor protein expression), which is typically an aggressive tumor that does
not respond to targeted chemotherapy agents [30]. Interestingly, triple-negative breast
cancers of women often express AR and might respond to ADT or AR blockade [30]. Yet,
triple-negative breast cancers that lose AR expression often have characteristics of primitive
basal-like cancers with poor clinical course [31]. This suggests that AR signaling may help
induce new breast cancers, but “dedifferentiated” primitive cancers may downregulate
AR expression because they are driven by hormone-independent mechanisms. Similar
phenomena have been observed in other cancers that become independent of the signaling
molecules that characterize cells from the same tissue of origin [32–34].
Hormone independence sometimes arises early in tumor progression. Breast ductal
in situ carcinomas likely are precursors of invasive carcinomas. A few of these non-
invasive tumors are “triple-negative” and express other markers characteristic of highly
aggressive invasive breast cancers [35,36]. This evidence suggests that steroid hormone
receptors and other important drivers of breast tissue growth can be lost early in the
evolution of a few tumors. Resistance to drugs that affect hormone stimulation and
signature signaling pathways fits into Hanahan and Weinberg’s carcinogenesis and cancer
progression paradigm [32]. Tumors are characterized by increasing independence from the
growth factors that normally control cell proliferation in their tissue of origin. Independence
from particular growth signals may occur early, as noted above. Due to their high mutation
rate, other cancers unleash a repertoire of new growth mechanisms and acquire growth
signal independence later in tumor evolution [32].
3. UBC as an Endocrine Tumor
Growing evidence indicates that UBC, like PCa, is driven by androgens and AR
signaling. Distinct from most epithelial tissues, urothelium is derived from the urogenital
sinus, which also gives rise to the prostate in males [37]. We speculate that the prostate
and the urothelium share properties, such as AR-dependence. Many human UBC cell
lines and 13–78% of UBC tumors express AR in both men and women [38–40]. Moreover,
stromal cells express AR in about half of UBC tumors [38]. The AR gene is polymorphic for
exon 1 CAG repeat number, which encodes a tract of glutamine amino acid residues [41].
CAG repeat number inversely correlates with AR transcription and AR signal strength [41].
This suggests that the CAG-encoded polyglutamine tract interferes with AR transcription
and possibly with AR protein function. Men with low AR CAG repeats are more likely
to develop locally invasive or metastatic PCa [40,42]. Similarly, male UBC patients had
fewer AR CAG repeats than control males, suggesting that AR signaling also may drive
UBC [40,43].
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In addition to spontaneously arising cancers, carcinogen-driven UBC in mice were accel-
erated by AR and androgens. The carcinogen, BBN (N-butyl-N-(4-hydroxybutyl)nitrosamine),
more quickly induced UBC in male mice than in female mice. BBN-induced male UBC
was reduced by surgical or medical ADT and an AR-blocking drug [40] or by knockout of
the AR gene [44]. Interestingly, AR knockout protected both male and female mice from
BBN exposure, eliminating UBC incidence and greatly reducing bladder hyperplasia [44].
Finasteride (a 5α-reductase inhibitor that prevents the conversion of testosterone to the
more potent androgen, DHT; Figure 1) was marginally protective [40]. In female mice,
androgen treatment increased bladder tumor incidence. The significant ADT effect and the
marginal protection offered by finasteride suggest an AR signaling threshold. 5α-reductase
inhibitors prevent conversion of testosterone to the more active DHT, but are associated
with higher testosterone levels [45]. Therefore, mouse UBC might be driven equally by
physiological male androgen signaling and by moderate androgen signaling found in the
presence of 5α-reductase inhibitors. This parallels findings in human PCa—men with the
lowest 10% of testosterone levels were relatively protected from PCa, but men with the high-
est testosterone levels had no increased risk compared to men with moderate levels [46].
Furthermore, testosterone replacement therapy does not increase PCa risk [47]. If there
is an androgen threshold in UBC, we would speculate that the relatively high androgen
levels in men impart a greater UBC risk. In summary, a growing body of evidence shows
how AR and androgen signaling promote UBC development and progression. Based on
this evidence, targeting AR is predicted to reduce UBC recurrence and progression.
Transcriptional coactivator proteins help mediate AR-dependent gene transcription
and support AR protein stability [48]. The steroid hormone receptor coactivator, NCOA3
(AIB1), was overexpressed in about a third of human UBC cases, which was an indepen-
dent predictor of poor progression-free survival in multivariate regression analysis [49].
Furthermore, NCOA3 knockdown slowed human tumor xenograft growth in mice and
NCOA3 enforced expression increased tumor growth [49]. SiRNA knockdown of coactiva-
tor RNA in AR-positive UBC cell lines decreased androgen-induced proliferation [39]. AR
coactivators NCOA1, NCOA2, NCOA3, CREBBP, and EP300 were expressed in 86–100%
of UBCs, even though AR was present in a minority of UBCs [39,40]. The presence of
these coactivators when AR was absent suggests that they cooperate in non-AR-directed
transcription.
The mechanisms by which androgens and AR control UBC are not fully understood.
UM-UC-3 UBC cells selected for AR expression had higher clonogenic growth and greater
migration than parental UM-UC-3 cells after androgen treatment in vitro, suggesting that
AR drives UBC growth and metastasis [50]. As in prostate cancer [48], some data suggest
that UBC may initially present with androgen dependence but progressive UBC may lose
this dependency [40,51]. Izumi et al. [52] reported that AR, estrogen receptor-α (ERα), and
ERβ nuclear staining were more frequent in normal-appearing urothelium than in UBC.
In men receiving ADT, AR-negative UBC went on to recur in 12 of 28 patients (43%), but
AR-positive UBC recurred in only 11 of 44 patients (23%). In multivariate analysis of men
receiving ADT [52], only two factors were significant, UBC AR expression and UBC tumor
number (single vs. multiple). This suggests that ADT delays or prevents UBC recurrence in
AR-positive tumors (Table 1). AR expression level in normal urothelium did not correlate
with tumor recurrence and tumor cell ERα and ERβ expression did not predict recurrence.
In another study, Izumi et al. [53] investigated UBC recurrences in patients who were
also treated for PCa (Table 1). UBC recurrence was less frequent in the ADT-treated PCa
group (5-year actuarial recurrence-free survival: 76% v 40%; p < 0.001). In those men with
UBC recurrence, ADT was associated with fewer recurrence episodes (5-year cumulative
recurrence: 0.44 vs. 1.54; p < 0.001). Most patient characteristics would have been predicted
to disfavor the ADT group (worse PCa disease, older age), but brachytherapy was higher in
the non-ADT group and radiation is a UBC risk factor [54]. In addition, a greater percentage
of the ADT group received BCG infusions [53], which prevent UBC recurrence [55–57].
Although intriguing, conclusions are weakened because the study was retrospective and
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multicenter [53]. Shiota et al. [58] followed 228 men for recurrence of bladder cancer for an
average of 3.6 years; 32 of 196 men received ADT or dutasteride (a 5α-reductase inhibitor)
for concomitant PCa. UBC recurred in four men with ADT or dutasteride (12.5%) and
59 men without (30.1%). Progression to muscle-invasive cancer occurred in none of the
men on ADT or dutasteride and in six men who were not on these therapies (3.1%). ADT
(or dutasteride) was associated with significantly decreased risk of intravesical recurrence
(hazard = 0.4, p = 0.024). Although sample size was small and follow-up time was short,
this study suggests that ADT or dutasteride may prevent UBC recurrence in high risk
patients. In patients already diagnosed with UBC, retrospective studies have suggest that
both overall and cancer-specific survival were superior in 5α-reductase inhibitor users [59].
ADT may protect UBC with low-risk disease, but not patients with high-risk disease [59].
This correlates with declining AR expression by more advanced UBC tumors [40,50].
Table 1. Effects of Androgen-Based Therapy on UBC Recurrence, Progression, and Mortality.
Treatment Effect on UBC Support * Ref.
ADT ↓ recurrence # Yes [52]
ADT ↓ recurrence Yes [53]
ADT or 5α-R $ ↓ recurrence, progression Yes [58]
5α-R ↓ incidence,↔mortality Yes/No [60]
5α-R ↓ recurrence Yes [61]
5α-R ↔ recurrence, ↓ deaths No/Yes [62]
5α-R ↔ incidence No [45]
* Support for the hypothesis that UBCs respond drug treatment. # Recurrence was less in men with AR+ UBC $
5α-R, 5α-reductase inhibitor drug.
Based on 13-year follow-up of the Prostate, Lung, Colorectal, and Ovarian (PLCO)
database (Table 1), men who were treated with finasteride (a 5α-reductase inhibitor) at any
time during the survey had lower UBC incidence (hazard = 0.634), when also controlling
for age and smoking [60]. However, there was a non-significant trend toward higher
UBC grades in finasteride users and there was no significant difference in UBC-caused
mortality [60]. The retrospective study was limited because finasteride dose and some risk
factors (such as alcohol consumption) were not known. In two retrospective insurance
record reviews in Taiwan (Table 1), investigators found that 5α-reductase inhibitors did [61]
or did not [62] reduce the risk of UBC recurrence. One of the studies (Table 1) found that 5α-
reductase inhibitors prevented UBC deaths [62]. Interestingly, amplification of the gene that
encodes 5α-reductase was found in 12% of UBC queried in the TCGA database [61]. In a
systemic review, ADT or 5α-reductase inhibitors had mixed results in preventing UBC [59].
Interpretation of these studies is difficult because of the expected lower complications
of urinary tract infection and hematuria in 5α-reductase inhibitor users that may have
led to fewer exploratory cystoscopies and, therefore, fewer incidental UBC diagnoses.
This may have decreased UBC discovery in the 5α-reductase inhibitor group. Despite
the number of manuscripts showing that ADT and 5α-reductase inhibitors reduce UBC
incidence or recurrence, it should be noted that most of these studies had methodological
limitations [63].
A double-blind prospective study was conducted on subjects in the MTOPS trial [45].
Subjects were monitored for compliance, something that is impossible with retrospective
studies. As expected, serum DHT levels were lower and testosterone levels were higher
among the subjects treated with 5α-reductase inhibitor drug [45]. UBC incidence was not
statistically different in men with and without 5α-reductase inhibitor treatment (Table 1).
Thus, there is support for use of ADT in UBC, especially when the tumor expresses AR.
However, the literature on 5α-reductase inhibitor treatment is inconsistent (Table 1). Litera-
ture inconsistency correlates with weak findings in experimental animals [40]. One possible
interpretation of these results is that there is a threshold effect of androgen signaling in
promoting UBC—the moderate amount of androgen signaling retained in 5α-reductase
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inhibitor users may be sufficient to promote UBC, whereas the lower level of androgen
signaling under ADT may reduce UBC risk.
Researchers have investigated a possible correlation between AR expression and
increased transformation of normal bladder urothelium to UBC. In a meta-analysis, AR
status in UBC correlated neither with patient gender, nor with tumor size, stage, grade, or
progression [51]. In contrast, three studies showed that lack of tumor AR expression was
strongly associated (odds ratio, 0.41) with more frequent UBC recurrence [51], although
discordant results have been reported [40,64]. Most studies showed that AR status did
not predict survival [64]. Hsu et al. [65] found that bladder-specific AR knockout mice
developed fewer and less aggressive BBN chemical-induced UBCs. They also showed
that AR acted through a p53-mediated pathway, allowing more bladder cancer cells to
survive apoptosis [65]. This suggests that AR signaling increases tumorigenesis and tumor
cell survival. Luna-Velez et al. reported that AR expression was significantly lower in
muscle-invasive disease than in non-muscle-invasive UBC; AR expression was the lowest
in the most advanced T3 and T4 disease, compared with T1 UBC [50]. On the other hand,
Mir et al. [66] did not find a significant AR-related difference in time to death or rate of
recurrence in a study of almost 500 patients with UBC muscle-invasive tumors. Among
the patients studied, 12.9% of the tumors expressed AR and there was no significant sex
difference. It is likely that AR affects UBC in complex ways that depend on cancer stage.
AR signaling seems to initiate more UBCs, but we do not know whether AR signaling
causes more aggressive disease. Given that many tumors grow increasingly independent
of hormones and signaling pathways during cancer progression [32], it would not be
surprising if androgens drive early UBCs, but not late UBCs.
In a separate aspect of AR signaling, Miamoto’s group [67] showed that androgens
increased resistance to cisplatin-based chemotherapy of AR-expressing UBC cell lines.
In a complementary fashion, AR-blocking drugs increased cisplatin sensitivity [67,68].
Among the mechanisms responsible, Miamoto’s group [69] found that androgens reduced
expression of an RNA- and ribosome-processing protein, BRIX1 (BXDC2), in UBC cell lines.
Furthermore, AR and BRIX1 showed complementary expression patterns in UBC tissue
sections [69]. Cisplatin-resistant cell lines increased BRIX1 expression [69], but BRIX1 mech-
anisms in UBC are not clear. Although treatment of cell lines in vitro cannot be directly
translated to the clinic, these studies suggest that AR antagonists may act synergistically
with cytotoxic chemotherapy in UBC patients. As mentioned above, intravesicular BCG
treatment commonly follows NMIBC resection. BCG vaccination has many nonspecific
effects, including nonspecific induction of “trained” immunity and lower levels of inflam-
matory serum proteins [70]. It is notable that the reduction of inflammatory proteins was
much more pronounced in men than in women and correlated with pre-vaccine testos-
terone levels in males [70]. Preclinical data showed that BCG was more effective when
AR was downregulated or absent, or in the presence of AR antagonist drugs [71,72]. The
mechanism is possibly related to the Rab27b vesicle protein, which may allow UBC to
exocytose previously ingested BCG [71]. In a retrospective analysis of human biopsy
samples, both AR and Rab27b protein expression correlated with higher UBC recurrence
rates [71].
UBC incidence and the total number of UBC-related deaths are much higher in males
than in females [3], but women suffer higher stage-for-stage progression and mortality
than do men [73–75]. Sadly, some of the greater mortality in women may be related to
delayed treatment or different treatment opportunities offered to females [74]. For example,
urological investigation of hematuria is delayed in female patients compared with male
patients. As an exception to that general finding, women may have a better cancer-specific
mortality than men following neoadjuvant chemotherapy plus radical cystectomy [76]. This
conclusion, which was based on two small studies [76], requires confirmation. However,
women have worse outcomes following transurethral resection of NMIBC and post-surgery
chemotherapy [74]. In early stage Ta tumors, women are more likely to have the GS1 UBC
subtype. These tumors have high rates of proliferation, mutations, genetic instability, and
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loss of chromosome 9 or deletion of 9q [77]. These deletions remove TSC1, a negative
regulator of the mechanistic target of rapamycin (mTOR). Consequently, GS1 NMIBCs have
gene expression changes that suggest altered metabolism, including elevated glycolysis [77].
Consistent with overall worse outcomes for women, multivariate analysis suggested that
female sex was a risk factor for recurrence after BCG therapy [74,78], despite the well-
documented superior responses by women to a variety of vaccines [79–84]. de Jong and
colleagues [85] found that, compared with men, women were more likely to have the
aggressive basal/squamous subtype, whereas men were more likely to have luminal
papillary and neuroendocrine-like subtypes. It may be significant that advanced UBC
in men had higher androgen response activity across all luminal subtypes, compared
to advanced UBC in women [85]. These findings support the concept that androgens
help initiate UBC. However, some UBCs progress to a more aggressive form, becoming
androgen-independent through AR loss or other means. One molecular consequence of
AR loss in advanced UBC is that AR suppresses transcription of CD44 [86], which encodes
a cancer stem cell marker that mediates UBC aggression [87]. AR mRNA negatively
correlated with CD44 mRNA in UBC, both before and after chemotherapy [86]. Due to
lower androgen levels in women, it should not be surprising that the smaller numbers
of UBC female patients are enriched for more aggressive androgen-independent cancers.
In contrast to androgens, the role of estrogens in UBC is less clear. Estrogens appear to
suppress UBC development but may promote UBC progression [74]. Treatment of mice
with the selective estrogen receptor modulator, tamoxifen, greatly reduced bladder tumor
formation and muscle-invasive tumors in female mice fed the BBN carcinogen [88]. Hsu
et al. [89,90] reported that female mice lacking ERβ were less susceptible to carcinogen-
induced UBC, whereas female mice lacking ERα were more susceptible. These apparently
discordant results suggest that there are distinct roles for ERαα and ERββ homodimers, in
addition to ERαβ heterodimers.
4. Androgenic Immune Suppression
Gender-based immune disparity is well-documented [81,91,92]. Men suffer more
infectious disease complications [93,94] and cancers [3,95–97] than do women, includ-
ing at elderly ages. Women generally respond better to vaccines, although exceptions
exist [79–84]. Autoimmune disease can be attributed to excess immunity and women are
more susceptible to the most common autoimmune diseases [83]. Sex differences are ob-
served in children as well. Infant boys are significantly more susceptible to infections than
infant girls, a difference that is attributed to the androgen surge that boys experience at
birth [83,98–100]. In addition to androgens, male vs. female immune response differences
might be linked to estrogens, progesterones, X-linked genes, and socioeconomic factors. In
the current pandemic, male gender has been found to be a strong risk factor for COVID-19
disease and death, whether or not overall SARS-CoV-2 infection rate is higher in men than
in women [101,102].
Early hematopoietic precursor cells express AR RNA in mouse bone marrow and in hu-
man bone marrow and cord blood [103]. However, some differentiated hematopoietic cells
lose AR expression [103]. Using immunohistochemistry, Mantalaris and colleagues [104]
detected AR protein in several bone marrow elements, including stromal cells, endothelial
cells, Mϕ, and other myeloid cells (although not eosinophils). AR expression was affected
neither by sex nor by age (range 1–92 years). However, Mantalaris et al. [104] did not detect
AR protein in bone marrow lymphocytes.
5. Androgens and Innate Immunity—Myeloid Cells
Myeloid cells are pivotal in anti-cancer immunity [32,105–107]. Depending on the
local cytokine and cellular microenvironment, myeloid cells promote tumor angiogenesis
and growth and suppress immunity. Alternatively, myeloid cells present tumor antigens to
T cells and cooperate with NK cells to eliminate cancer cells [32,105–115]. Developing mye-
locytes respond to androgens, but specific myeloid subsets become androgen-independent
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at distinct differentiation stages. The common myeloid progenitor is stated to express AR
RNA [25]. The common dendritic cell and the granulocyte–macrophage progenitor do
not express AR, but mature myeloid cells do, including macrophages (Mϕ), monocytes,
neutrophils (both band cells and segmented), and mature mast cells [25,104].
Among the myeloid cells, Mϕ are particularly important because they regulate tissue
homeostasis and produce several proinflammatory cytokines [108,114,116–121]. Myeloid-
specific AR gene deletion and AR-blocking enzalutamide reduced monocyte precursors
in the mouse bone marrow [122]. AR knockout also reduced the proportion of classical
monocytes [122], which are thought to enter tumor and inflammatory sites and develop
into macrophages or dendritic cells. Gonadectomy elevated pro-inflammatory responses
by increasing expression of toll-like receptor 4 (TLR4) by male murine Mϕ [123]. Some
results, however, suggest that testosterone promotes specific proinflammatory cytokines in
certain contexts [124–126]. Thus, testosterone and AR signaling may differentially affect
Mϕ depending upon the Mϕ source, the type of stimulus, and the cytokine secreted. Mϕ
cells involved in wound healing express AR. Wound healing is slower in males than in
females, but healing has been shown to be accelerated by an AR antagonist, flutamide, and
by myeloid-specific AR gene deletion [124,125]. Importantly, wound healing correlated
negatively with testosterone levels in elderly men [124].
Neutrophils, the most abundant blood leukocyte, respond rapidly to bacterial infec-
tions and many cancers [127]. Androgens promote neutrophil differentiation—AR-deficient
mice, androgen insensitive mice, and AR blocker-treated patients are neutropenic [128,129].
Following treatment with stanozolol, a testosterone analog, female mice increased neu-
trophil maturation rate [130]. However, the mechanisms by which AR signaling affects
neutrophil function have not been fully elucidated [131]. Some authors have shown that
androgens suppress neutrophil production of proinflammatory cytokines and instead
promote anti-inflammatory IL-10 production [132]. These data suggest that androgens
promote neutrophil differentiation, but dampen neutrophil inflammatory actions.
Dendritic cells (DCs) present antigens to T cells and affect NK cell function [109–113,133,134].
DCs synthesize IL-15 and present it on their cell surface to stimulate NK cells and memory
T cells to mature, divide, and survive [110,135–137]. DCs stimulate NK cells to synthesize
granzyme B and become cytotoxic [110,135,137,138]. Only a few studies have addressed
possible direct effects of AR and androgens on DCs, but, in general, they seem to depress
DC immune function [25]. This is controversial because some investigators have shown
that DCs do not express AR [139]. DCs isolated from male mice after brain LCMV infection
were less activated than in female mice [140]. Male sex reduced expression of DC MHCII
and CD86 [140]. These molecules, respectively, present antigens at the cell surface to
CD4 T cells [141] and co-stimulate T cell CD28, which promotes T-cell differentiation and
survival [142]. Castration increased expression of MHCII, CD86, and other co-stimulatory
molecules [143].
6. Androgens and Innate Immunity—NK Cells
NK cells kill both virus-infected cells and cancer cells, including metastases, without
antigen specificity or prior immunization [115,144–150]. Comprising 5–15% of blood
lymphocytes in healthy people, NK lymphocytes are defined by CD56, CD16, or NKp46
(CD335) expression in the absence of the CD3 T-cell receptor [144–146]. NK cell activation
is regulated by multiple receptors [144–146]. Cell surface MHC class I molecules (MHCI,
termed HLA class I in humans) present antigenic peptides to CD8 cytolytic T lymphocytes,
which then divide, secrete IFN-γ and other cytokines, and kill antigen+ cells [141,151]. In
addition to stimulating CD8 T cells, MHCI molecules strongly modulate NK cell responses
by engaging NK cell KIR, NKG2A, and LILRB1 inhibitory receptors [144,146,152,153]. NK
cells also express many stimulatory receptors [144–146]. For example, NKG2D binds to
stress-activated ligands that are preferentially expressed on tumor cells and virus-infected
cells [144,146,148,154]. When confronting stress-activated ligand-positive tumor cells,
antibody blockade of NKG2D prevents robust NK cell activation [154].
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AR may affect NK cell development. Acyline-mediated chemical castration (ADT)
for two weeks increased circulating NK cells in men [155]. Testosterone replacement
prevented these changes. After 4 weeks of recovery from ADT, NK cell number returned to
normal levels; CXCR1 and NKG2D expression did not significantly change [155]. These
findings indicate that androgens control human NK cell numbers. In the elderly, the
immature CD56bright to mature CD56dim NK cell ratio was significantly higher in women
than in men [156]. Female CD56dim NK cells had higher cytotoxic granule exocytosis
in response to K562 tumor cells and higher IFN-γ made in response to cross-linking of
NKp46. Plasma IL-15, a cytokine required for NK cell development and survival, did not
differ by gender [156]. Therefore, although the mechanisms of the gender differences were
not identified, the results suggest that testosterone suppresses NK cell activity in elderly
humans. We did not detect AR mRNA in either CD56bright or CD56dim peripheral blood
NK cells (data not shown); therefore, the effects of testosterone on mature NK cells likely
are indirect. We further investigated whether androgens affected NK cell activity in the
context of cancer treatment. After obtaining informed consent, five men were studied
before and after ADT for metastatic PCa. The study was IRB-approved and consistent
with the Helsinki Declaration. Peripheral blood was removed by venipuncture and the
ability of NK cells in a mononuclear cell preparation to produce a chemokine (MIP-1β) was
compared pre- and post-ADT. Both IL-15 and IL-12/IL-18 stimulated significantly higher
MIP-1β responses post-ADT, with the IL-2-stimulated responses trending higher (Figure 2).
Several stimuli failed to significantly increase IFN-γ or cytotoxic responses post-ADT. This
shows that NK cells from men receiving ADT were not globally activated, but selectively
produced MIP-1β in response to IL-15 and IL-12/IL-18 cytokine stimuli. Although many
changes take place with ADT initiation, including a reduction of PCa mass, our results
are consistent with the hypothesis that androgens suppress NK cell MIP-1β responses to
cytokines and that ADT relieves the suppression.
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7. Androgens and Adaptive Immunity—B Cells
B cells both activate and carry out adaptive immunity. Firstly, B cells stimulate
a special class of CD4 T follicular helper cells in the germinal center [157]. Later in
the immune response, B cells develop into plasma cells that secrete antibody, which
protects the host by several mechanisms [158]. In general, women produce relatively more
antibody after vaccination [80,81]. Low testosterone levels in men predict more B cells
and higher response to vaccines and to infection [80,83]. Research suggests that mature
B cells do not express AR; therefore these effects may be exerted by other leukocytes
or on B-cell precursors when the AR is expressed [159–161]. Several lines of evidence
show that AR signaling impedes B-cell development. [159,162–164]. Experiments with
chimeric mice that expressed AR exclusively on either stromal cells or lymphoid cells in the
bone marrow showed that stromal cell AR is essential to inhibit the B-cell lymphopoiesis
typically observed with androgen treatment [164]. This suggests that the B-cell response
to androgens is mediated by stromal cells. In contrast to these findings, B-cell-specific AR
knockouts have been shown to elevate B-cell lymphopoiesis, suggesting that mouse B-cell
precursors are direct androgen targets [164]. The effect of the general AR knockout was
more pronounced than the B-cell-specific AR knockout, suggesting that both B-cell and
stromal AR suppress B-cell development. Further studies have shown that DHT causes
stromal cells to produce transforming growth factor-β, an anti-inflammatory cytokine
that dampens immune responses. Relevant to this discussion, transforming growth factor
β suppresses IL-7 production, a cytokine that is required for B-cell proliferation and
differentiation [165].
8. Androgens and Adaptive Immunity—T Cells
In comparison with B cells, T-cell response to androgens is more sustained and di-
rect [84]. AR is highly expressed in lymphoid precursor cells and in supporting cells—
marrow stromal cells and thymic epithelial cells [166]. It was established more than a
century ago that castration causes thymic hypertrophy, which suggests that androgens
regulate T-cell development [91,167–170]. Although AR has been detected in thymocytes,
experiments with chimeric mice showed that thymic involution required AR expression in
stromal cells, but not in bone-marrow-derived T lymphocyte precursors [166,169]. In a key
molecular step, androgens reduce thymic epithelial expression of δ-like 4, a notch ligand
that is required for T-cell maturation [91,171].
Mature T cells appear to express both classic cytoplasmic AR and a plasma membrane
androgen receptor [13–15,161,172–174]. Exogenous androgen treatment skews mouse
T-cell activation, proliferation, and differentiation, and inhibits T-cell-dependent anti-
body production [10,25,80,83]. These effects are likely due to a combination of intrinsic
T-cell effects [172] and depression of antigen-presenting cell MHC and costimulatory
molecule expression or cytokine production [123–126,140,143]. Thus, androgens affect both
T-lymphocyte development and mature T cells.
The study of androgen regulation is complicated by the many classes of T cells, each
with unique functions. CD4 T-helper 1 (Th1) cells are proinflammatory and produce cy-
tokines that stimulate cell-mediated and innate responses, which help prevent tumors
and clear intracellular bacteria and viruses [175]. Kissick et al. [172] showed that testos-
terone reduced CD4 Th1 differentiation by upregulating protein tyrosine phosphatase,
non-receptor type 1 (Ptpn1), which negatively regulates many cellular processes. T cells
expressed less Ptpn1 in PCa patients undergoing ADT than in control PCa patients [172]
and (Haydn T. Kissick, personal communication 12 April 2019). CD4 T-helper 2 (Th2)
cells control humoral immunity and the clearance of extracellular pathogens [175]. As
with Th1 cells, androgens diminish Th2 responses [176]. Th2 cells also quell inflamma-
tory immune responses by secreting anti-inflammatory cytokines [175,177]. Experimental
autoimmune encephalomyelitis is a commonly used model for multiple sclerosis, a de-
myelinating autoimmune disease. In experimental autoimmune encephalomyelitis cell
culture and mouse models, androgen treatment increased IL-10 production and decreased
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demyelinating disease in female mice [178]. The underlying mechanisms are not known,
but IL-10 generally seems to protect against autoimmune disorders [177]. Androgens
stimulated mast cells, which activated innate lymphoid cell type 2 (ILC-2) cells, which
in turn activated a Th2-like response [179,180]. Interestingly, testosterone, Fc receptor
cross-linking, and Mycobacterium tuberculosis all induce IL-33 production in male, but
not in female, bone-marrow-derived mast cells [179]. In specific inflammatory diseases,
IL-33-driven Th2 responses ameliorate disease pathology [181].
Regulatory T cells (Treg) modulate the immune response by reducing inflammation
and by modulating response to self-antigens [182,183]. Regulatory T cells put the brakes
on a variety of cells, including NK cells [184,185]. Androgens increase Treg cells in vivo
and in vitro. Waleki et al. showed that this modulation was related to androgen-dependent
acetylation of histone H4 at the FOXP3 locus, a gene that is needed for Treg cells to
differentiate in the thymus and to function in the peripheral tissue [174,186]. Androgen
modulation of FoxP3 expression is one of many mechanisms by which androgens suppress
immunity.
9. Chromosomal Effects on UBC
In healthy females, each cell randomly silences one X chromosome at an early stage of
embryogenesis [187]. However, X chromosome silencing is incomplete and about 15–25%
of these genes are transcribed to at least the 10% level on the active X, and a few at nearly
100% [188,189]. Some genes always escape complete inactivation, and some vary between
XX females. Escape from complete silencing also differs by tissue and stage of development
and increases with entry into the cell cycle [190,191]. Thus, compared to males, females
express significantly more mRNA from certain X-linked genes. UBC and other solid
tumor incidence are increased in patients with Turner syndrome, which is characterized
by XO, a single sex chromosome [192,193]. Similarly, solid tumor incidence is decreased in
Klinefelter syndrome patients, who carry at least 2 X chromosomes and 1 Y chromosome,
have small testicle size, and reduced testosterone [192]. As in females, X chromosome
inactivation is incomplete on supernumerary X chromosomes in Klinefelter males [194].
Both Turner syndrome and Klinefelter syndrome patients have altered sex hormone levels,
so sex hormones, X chromosome number, or both might affect cancer risk. To separate
biological sex and associated hormone expression from sex chromosome composition,
investigators have created “four core genotype” mice [195]. These animals have the sex-
determining SRY gene deleted on the Y chromosome and inserted into an autosome,
allowing biological sex (and sex hormones) to be separated from X and Y chromosome
composition. Using the “four core genotype” mice, Kaneko and Li [196] studied UBC
responses to the BBN carcinogen. XY male mice were most susceptible, followed in order
by XX males, XY females, and XX females. Survival was significantly different in each group.
Thus, both biological sex and sex chromosome composition contributed to UBC risk in mice.
Investigating the mechanism involved, Kaneko and Li [196] showed that the X-linked lysine
demethylase 6A (KDM6A) gene is expressed more highly in the urothelium of XX males
and females than in the urothelium of XY males and females [196]. This is because females
express KDM6A from both X chromosomes, escaping silencing [197,198]. Mechanistically,
KDM6A reverses the action of EZH2 methylation, which inhibits the transcription of
multiple genes [199,200]. These mouse findings are relevant to human disease. UBC from
female patients had more KDM6A expression than did UBC from male patients [77,196].
Furthermore, low tumor KDM6A expression was associated with higher UBC tumor stage
in women, but not in men. KDM6A mutations and low mRNA levels correlated with poor
disease-free survival in women, but not in men [196]. KDM6A is mutated in several cancers,
but the highest rates of mutation (20–29%) are found in UBC, with most of the genetic
alterations being pathogenic nonsense, frameshift, or splice site mutations [199,201–203].
An exciting finding is that loss of KDM6A in a UBC xenograft model predisposed tumor
cells to epigenetic therapy, which diminished in vivo tumor growth and increased natural
killer cell attack [203]. In addition to KDM6A, Dunford et al. [204] found five other X-linked
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genes (ATRX, CNKSR2, DDX3X, KDM5C, and MAGEC3) with loss of function mutations
or copy number changes that were more frequent in men than in women in many cancer
types. This sex-linked association was highly significant, as it was found in 6 out of
783 X chromosome genes but in zero of 18,055 genes from autosome chromosomes or
pseudoautosomal X chromosome regions [204]. Although we do not fully understand how
most of these X chromosome genes contribute to cancer, their incomplete allelic inactivation
may protect women.
The Y chromosome also affects cancer risk, but functions differently [205]. From
an analysis of 1153 elderly men, partial loss of the Y chromosome in peripheral blood
was associated with increased non-hematological cancer mortality. Men who had lost the
Y chromosome had a median survival time of 5.5 years shorter than patients who had
an intact Y chromosome [205]. More relevant to this discussion, the Y chromosome is
uniformly missing from many male UBC cases [206]. In other cancers with a defective
KDM6A allele on the X chromosome, the Y chromosome may be present in the cell, but
may severely limit gene expression [202]. These findings suggest the possibility of one
or more Y-linked tumor suppressor genes. One candidate for the Y chromosome tumor
suppressor gene is KDM6C (also known as UTY), which is a paralog of KDM6A, mentioned
above. Ahn et al. [207] found that 23% of male UBC cases had deleted KDM6C; the KDM6C
deletion rate was 67% in UBC that also had an X chromosome KDM6A mutation. Other
investigators found KDM6C copy number loss or Y chromosome loss in 12–42% of male
UBC cases and this was more common in UBCs that carried KDM6A mutations [77,199].
Thus, the X chromosome KDM6A and the Y chromosome KDM6C each may suppress
tumor growth and partially compensate for each other in males.
10. Sex Differences Not Directly Attributed to Hormones or Sex Chromosomes
Some sex-related differences do not appear to be directly related to sex hormone
differences or sex chromosomes. For example, chromosome 3 VGLL3 shows female-biased
expression in skin, salivary glands, and in monocytes [208]. Keratinocytes from female
subjects expressed more VGLL3 RNA, whether there was estradiol, testosterone, or no sex
hormone in culture [208]. VGLL3 is of interest as it may act as a tumor suppressor gene
in epithelial ovarian cancer [209], but VGLL3 expression is a marker for poor outcome in
stomach adenocarcinoma and in PCa [210,211]. Therefore, VGLL3 is differentially expressed
by sex in some tissues and alters tumor outcome. In another example, Sabag et al. [212]
found that hemizygous deletion of the chromosome 10 EGR2 (Krox20) gene, whether in
whole animals or in myeloid cells, increased bone resorption by osteoclasts in female mice,
but not in male mice. The phenomenon continued to be manifested in preosteoclast cell
lines cultured several days in vitro in the absence of any sex hormones. However, further
investigation [212] showed that the sex differences were manifested only in preosteoclast
cells that had been derived from post-pubertal mice (8 weeks old) but not harvested
from mice before puberty (4 weeks old). These and other data [213,214] suggest that sex
hormones cause epigenetic differences in the genomes of male and female animals, which
persist long after sex hormones are removed. It is relevant to note that most genes that show
sex-specific expression are driven by distinct sets of transcription factors in male and female
tissues, even when the transcription factor levels do not vary by sex [215]. This strongly
suggests that the sex differences establish distinct epigenetic landscapes, which persist
after direct sex hormone action. Many of the differentially expressed sex-specific proteins
are involved in methylation and presumably control epigenetic gene expression [215].
11. UBC and Natural Killer Cells
NK cells are the most common leukocyte in UBC tumors [216]. Using gene expression
data to deduce immune cell infiltration, several groups have reported that the presence of
NK cells predicts better UBC outcomes [203,217–220]. Importantly, the level of CD56bright
NK cells correlates with both cancer-specific survival and overall survival [216]. These data
are consistent with the idea that NK cells slow UBC progression. This idea is reinforced by
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findings that epigenetic therapy of KDM6A-deficient UBCs caused NK cell attack and tumor
regression in a preclinical model [203]. As mentioned above, NMIBC is often treated with
intravesical BCG instillation [55–57]. Now used for more than 40 years, BCG intravesicular
infusion is the longest continuously used cancer immunotherapy [55–57]. NK cells are
among many immune and non-immune cells that are required for BCG immunotherapy
success [55,221–225]. In other settings, BCG vaccination induces an elevated “trained
immunity” against multiple pathogens, including elevated in vitro NK cell responses
against non-cross-reactive microbes [226]. Surprisingly, intravesicular infusion of cytokine-
activated healthy donor human NK cells were reported to eliminate orthotopic human
UBC mouse xenografts [225]. If this study is confirmed and expanded to human patients,
it would suggest the potential for NK cell-based therapy.
UBC patient NK cells differ from those of healthy subjects. NK cells from UBC patients
expressed low levels of L-selectin (CD62L), which allows lymphocyte circulation through
lymph nodes, and low levels of stimulatory NKp30, NKp44, and NKp80 natural cytotoxicity
receptors, which are crucial for target cell killing and other NK cell activities [146,225,227].
IL-2 boosts NK cell responses in cancer patients [228]. Following subcutaneous IL-2 injec-
tion, circulating NK cell number increases [229]. Importantly, some melanomas and kidney
cancers respond to IL-2 injections [230]. However, IL-2 is a strong activator of regulatory
T cells, which dampen immune responses by both T cells and NK cells [183,228,231,232].
IL-15 is an alternative cytokine because it signals NK cells and memory T cells though the
same receptor β and γ chains as IL-2, but it renders effector cells refractory to regulatory
T-cell suppression [233–235]. Using NK cells as a therapeutic agent, healthy donor NK cells
were stimulated in vitro and then infused into hematopoietic stem cell transplant patients,
with NK cell responses boosted by IL-2 injection. This combined treatment prevented acute
myeloid leukemia relapse [236].
CSCs drive cancer progression and long-term proliferation by maintaining an un-
differentiated state and replacing partially differentiated cancer cells [32,237–241]. CSCs
resist radiation and many chemotherapeutic drugs, and account for metastases and post-
treatment tumor relapse [32,237,238]. NK cells preferentially target CSCs [225,242–245],
which suggests a possible therapeutic approach. UBC-derived NK cells killed the RT4
UBC cell line much more effectively after blocking MHCI [216], consistent with functional
MHCI-specific inhibitory receptors on UBC tumor-infiltrating NK cells. Although CSCs
may have relatively low or high MHCI expression, CSCs are NK susceptible because they
express abundant stimulatory ligands [242–245]. The NK-stimulating ligands expressed by
CSC include NKG2D ligands: MHC class I chain-related protein A and B (MICA and MICB)
and ULBP1. Killing of CSCs by NK cell sis primarily controlled through the interaction
of the NKG2D receptor and its ligands [225,245]. In mouse models, NK cells significantly
decreased UBC CSC number [225]. These data suggest that NK cells kill CSC and thereby
prevent bladder cancer recurrence.
12. Conclusions
In most non-reproductive tissues, men are more likely than women to develop cancer
and die of disease, and UBC is an outstanding example. Gender disparity has many
potential causes, including androgen-induced immunosuppression, androgen-induced
urothelial and neoplastic proliferation, greater male exposure to carcinogens, and the
protective effects of X chromosome genes in females. We predict that better understanding
the gender differences will to lead to more effective treatments in both men and in women.
Suppression of androgens [40] may reduce NMIBC recurrence, progression, and mortality
in men, and possibly in women. Knowledge that KDM6A and KDM6C are under-expressed
in UBC suggests that reducing EZH2 activity will effectively treat KDM6A/KDM6C-
defective UBC in both sexes [199,200]. Boosting immunity, especially NK cell immunity,
may lead to better outcomes in both sexes, especially in men. Although this review
largely focused on biological sex, social factors also are important: women often receive
delayed diagnostic testing and disparate treatment options. Finally, when urologists
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recognize that females and males are sometimes treated differently [74], outcomes may
improve. We believe that a better understanding of gender-specific disparities in UBC,
at the genetic, molecular, cellular, clinical, and cultural levels, will lead to more safe and
effective treatments for both male and female UBC patients. More research is urgently
needed.
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